Skip to content
About
Oncolytic Viruses
Immunotherapy Combinations
R&D Facility
Team
Company News
Corporate Investor Deck
Leadership Team
Board
Management Team
Our Technology
IVX037
IVX055
Pipeline
Scientific Presentations
Pre-clinical / discovery
Clinical
Therapeutic Strategy
Innovent Collaboration
Pipeline
Investor Centre
Corporate Deck
Company Announcements
In the News
ESG
Recruitment
Contact
Menu
About
Oncolytic Viruses
Immunotherapy Combinations
R&D Facility
Team
Company News
Corporate Investor Deck
Leadership Team
Board
Management Team
Our Technology
IVX037
IVX055
Pipeline
Scientific Presentations
Pre-clinical / discovery
Clinical
Therapeutic Strategy
Innovent Collaboration
Pipeline
Investor Centre
Corporate Deck
Company Announcements
In the News
ESG
Recruitment
Contact
Designation:
Co-Founder, CEO and Acting Chairman
Dr Malcolm McColl